Treatment landscape for presbyopia evolving toward noninvasive options
Noninvasive or minimally invasive approaches may be the solution for presbyopia before the onset of age-related cataract and a way to address the increasing need to perform close-range tasks.
“The treatments that are currently available have not met our needs,” OSN Cornea/External Disease Board Member Eric D. Donnenfeld, MD, said. “Glasses are an inconvenience. Contact lenses cause dry eye, and most people become intolerant after a while. Corneal inlays have not done well, and most of them have left the market in the United Sates. Finally, laser vision correction is not for everyone and has all the drawbacks of monovision. Multifocal IOLs are an excellent option but at a later stage when people develop cataract.”
Explore More Articles
VIDEO: New laser offers further improvement to laser scleral microporation
BOSTON — In this Healio Video Perspective from Eyecelerator@ASCRS, AnnMarie Hipsley, DPT, PhD, and George O. Waring IV, MD, FACS, discuss the latest advances in laser scleral microporation.Hipsley said that the GenII VisioLite laser for laser scleral microporation (LSM) is on the pathway to commercialization and may be available by the end of the year.
read moreInfluence of Ocular Rigidity and Ocular Biomechanics on the Pathogenesis of Age-Related Presbyopia
This chapter discusses ocular rigidity and ocular biomechanical dysfunction as they relate to the age-related pathogenesis of presbyopia. The major factors associated with presbyopia as they relate to ocular rigidity and ocular biomechanical dysfunction are highlighted. Furthermore, specific reference is made to modifying the biomechanical properties and structural stiffness of the scleral outer coat utilizing …
read moreLaser scleral microporation may solve biomechanical problem of presbyopia
CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Alex Lopez of Ace Vision Group discusses laser scleral microporation for presbyopia. Lopez said the GenII device can potentially deliver improved near vision without compromising distance vision in patients with presbyopia. The company plans to do a study in the United States in 2026, potentially leading to commercial availability in …
read more